MedElevator
Войти в исследования Digestive diseases (Basel, Switzerland) · 2026
Predictors of Incident High-Risk Varices in Patients with Hepatitis B-Related Cirrhosis Receiving Nucleos(t)ide Analog Therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chiu Yu-Chia, Tsai Hsin-Ju, Chen Chia-Chang, Lin Ying-Cheng, Lee Shou-Wu, Lee Teng-Yu
Аннотация
INTRODUCTION: In patients receiving nucleos(t)ide analog (NA) therapy for chronic hepatitis B (CHB)-related cirrhosis, routine endoscopic surveillance may be deferred in the absence of high-risk varices (HRV). We aimed to identify predictors of incident HRV in this population.
METHODS: This retrospective cohort study included patients with CHB-related cirrhosis who initiated NA therapy between March 2008 and June 2020 and were followed through May 2024. Eligible patients underwent baseline and on-treatment upper endoscopy. Patients with baseline HRV, prior variceal ligation, use of nonselective β-blockers, other viral hepatitis, alcohol overuse, or malignancy were excluded. The cumulative incidence of HRV and adjusted subdistribution hazard ratios (aSHRs) were estimated using competing-risk methods. A point-based risk prediction model was derived from multivariable regression coefficients.
RESULTS: Among the 110 included patients, 14 (12.7%) developed HRV over a median follow-up of 3.6 years (IQR, 2.0-5.6). In multivariable analysis, fibrosis-4 (FIB-4) ≥4.0 (aSHR 9.77; 95% CI, 1.45-65.7), coexisting metabolic dysfunction-associated steatotic liver disease (MASLD) (aSHR 6.37; 95% CI, 1.84-22.0), and albumin-bilirubin (ALBI) grade >1 (aSHR 3.02; 95% CI, 1.21-7.55) were independently associated with incident HRV and were assigned 3, 2, and 1 point, respectively, in the prediction model. At 3 years, the cumulative incidence of HRV was 1.5% (95% CI, 0-4.5) in the low-risk group (0-3 points) and 21.4% (95% CI, 8.0-34.8) in the high-risk group (4-6 points) (p = 0.001).
CONCLUSION: MASLD, FIB-4, and ALBI grade predict incident HRV in NA-treated CHB cirrhosis, enabling risk-stratified endoscopic surveillance.
METHODS: This retrospective cohort study included patients with CHB-related cirrhosis who initiated NA therapy between March 2008 and June 2020 and were followed through May 2024. Eligible patients underwent baseline and on-treatment upper endoscopy. Patients with baseline HRV, prior variceal ligation, use of nonselective β-blockers, other viral hepatitis, alcohol overuse, or malignancy were excluded. The cumulative incidence of HRV and adjusted subdistribution hazard ratios (aSHRs) were estimated using competing-risk methods. A point-based risk prediction model was derived from multivariable regression coefficients.
RESULTS: Among the 110 included patients, 14 (12.7%) developed HRV over a median follow-up of 3.6 years (IQR, 2.0-5.6). In multivariable analysis, fibrosis-4 (FIB-4) ≥4.0 (aSHR 9.77; 95% CI, 1.45-65.7), coexisting metabolic dysfunction-associated steatotic liver disease (MASLD) (aSHR 6.37; 95% CI, 1.84-22.0), and albumin-bilirubin (ALBI) grade >1 (aSHR 3.02; 95% CI, 1.21-7.55) were independently associated with incident HRV and were assigned 3, 2, and 1 point, respectively, in the prediction model. At 3 years, the cumulative incidence of HRV was 1.5% (95% CI, 0-4.5) in the low-risk group (0-3 points) and 21.4% (95% CI, 8.0-34.8) in the high-risk group (4-6 points) (p = 0.001).
CONCLUSION: MASLD, FIB-4, and ALBI grade predict incident HRV in NA-treated CHB cirrhosis, enabling risk-stratified endoscopic surveillance.